Queen's Birthday Honour for Professor Georgina Long
8 June 2020
Congratulations to Melanoma Institute Australia Co-Medical Director, Professor Georgina Long, who has been recognised in the 2020 Queen’s Birthday Honours List announced today by the Governor-General.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
‘This is well deserved recognition of Professor Long’s lifesaving work and ground-breaking research,’ said fellow MIA Co-Medical Director, Professor Richard Scolyer. ‘She has changed the face of melanoma treatment around the world and many thousands of people are alive today thanks to her intellect, determination and passion.
‘It is due to her research and thought leadership globally that the world is now realistically looking towards a day with zero deaths from melanoma,’ he added.
Professor Long is one of the world’s most renowned melanoma clinicians and researchers with her clinical trials tripling life expectancy for some advanced melanoma patients and essentially curing others.
She leads the clinical trials team at MIA, with a focus on targeted therapy and immune-oncology in melanoma, and is Principal Investigator on Phase I, II and III trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases.
Professor Long is a fierce advocate that recent advances and breakthroughs in melanoma treatment stem from the collective effort of the dedicated multi-disciplinary team at MIA that she co-leads with her colleague and friend Professor Scolyer.
In a double world first, she is the first woman and the first Australian to be President of the prestigious US-based Society for Melanoma Research (SMR). She has authored over 300 publications in melanoma clinical and translational research, including in the world’s leading scientific high-impact journals such as the New England Journal of Medicine and The Lancet, and has presented at hundreds of international conferences.
Professor Long’s Queen’s Birthday Honour follows numerous awards including being named the 2018 Outstanding Researcher of the Year at the NSW Premiers Awards for Outstanding Cancer Research and receiving the prestigious Research Australia, GSK Research Excellence Award in 2018 and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016.
‘Professor Long’s recognition in the Queen’s Birthday Honours List is a proud day for all of us here at Melanoma Institute Australia,’ said CEO Matthew Browne.
‘Not only is she saving lives and changing the future for melanoma patients around the world, but she is also an inspiring role model for all young Australians, particularly women, who may be working towards a career in science and medicine,’ he said.
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.